Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Controlled release of nerve growth factor from heparin-conjugated fibrin gel within the nerve growth factor-delivering implant

  • Lee, Jin-Yong (Department of Oral and Maxillofacial Surgery, Korea University Guro Hospital) ;
  • Kim, Soung-Min (Department of Oral and Maxillofacial Surgery, School of Dentistry, Seoul National University) ;
  • Kim, Myung-Jin (Department of Oral and Maxillofacial Surgery, School of Dentistry, Seoul National University) ;
  • Lee, Jong-Ho (Department of Oral and Maxillofacial Surgery, School of Dentistry, Seoul National University)
  • Received : 2013.10.23
  • Accepted : 2013.10.25
  • Published : 2014.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Although nerve growth factor (NGF) could promote the functional regeneration of an injured peripheral nerve, it is very difficult for NGF to sustain the therapeutic dose in the defect due to its short half-life. In this study, we loaded the NGF-bound heparin-conjugated fibrin (HCF) gel in the NGF-delivering implants and analyzed the time-dependent release of NGF and its bioactivity to evaluate the clinical effectiveness. Materials and Methods: NGF solution was made of 1.0 mg of NGF and 1.0 mL of phosphate buffered saline (PBS). Experimental group A consisted of three implants, in which $0.25{\mu}L$ of NGF solution, $0.75{\mu}L$ of HCF, $1.0{\mu}L$ of fibrinogen and $2.0{\mu}L$ of thrombin was injected via apex hole with micropipette and gelated, were put into the centrifuge tube. Three implants of experimental group B were prepared with the mixture of $0.5{\mu}L$ of NGF solution, $0.5{\mu}L$ HCF, $1.0{\mu}L$ of fibrinogen and $2.0{\mu}L$ of thrombin. These six centrifuge tubes were filled with 1.0 mL of PBS and stirred in the water-filled beaker at 50 rpm. At 1, 3, 5, 7, 10, and 14 days, 1.0 mL of solution in each tubes was collected and preserved at $-20^{\circ}C$ with adding same amount of fresh PBS. Enzyme-linked immunosorbent assay (ELISA) was done to determine in vitro release profile of NGF and its bioactivity was evaluated with neural differentiation of pheochromocytoma (PC12) cells. Results: The average concentration of released NGF in the group A and B increased for the first 5 days and then gradually decreased. Almost all of NGF was released during 10 days. Released NGF from two groups could promote neural differentiation and neurite outgrowth of PC12 cells and these bioactivity was maintained over 14 days. Conclusion: Controlled release system using NGF-HCF gel via NGF-delivering implant could be an another vehicle of delivering NGF to promote the nerve regeneration of dental implant related nerve damage.

Keywords

References

  1. Renton T, Yilmaz Z. Profiling of patients presenting with posttraumatic neuropathy of the trigeminal nerve. J Orofac Pain 2011; 25:333-44.
  2. van Steenberghe D, Lekholm U, Bolender C, Folmer T, Henry P, Herrmann I, et al. Applicability of osseointegrated oral implants in the rehabilitation of partial edentulism: a prospective multicenter study on 558 fixtures. Int J Oral Maxillofac Implants 1990;5:272-44.
  3. Kiyak HA, Beach BH, Worthington P, Taylor T, Bolender C, Evans J. Psychological impact of osseointegrated dental implants. Int J Oral Maxillofac Implants 1990;5:61-9.
  4. Ellies LG, Hawker PB. The prevalence of altered sensation associated with implant surgery. Int J Oral Maxillofac Implants 1993;8: 674-9.
  5. Bartling R, Freeman K, Kraut RA. The incidence of altered sensation of the mental nerve after mandibular implant placement. J Oral Maxillofac Surg 1999;57:1408-12. https://doi.org/10.1016/S0278-2391(99)90720-6
  6. Tay AB, Zuniga JR. Clinical characteristics of trigeminal nerve injury referrals to a university centre. Int J Oral Maxillofac Surg 2007;36:922-7. https://doi.org/10.1016/j.ijom.2007.03.012
  7. Gordon T. The physiology of neural injury and regeneration: the role of neurotrophic factors. J Commun Disord 2010;43:265-73. https://doi.org/10.1016/j.jcomdis.2010.04.003
  8. Wood MD, Sakiyama-Elbert SE. Release rate controls biological activity of nerve growth factor released from fibrin matrices containing affinity-based delivery systems. J Biomed Mater Res A 2008;84:300-12.
  9. Magill CK, Moore AM, Yan Y, Tong AY, MacEwan MR, Yee A, et al. The differential effects of pathway- versus target-derived glial cell line-derived neurotrophic factor on peripheral nerve regeneration. J Neurosurg 2010;113:102-9. https://doi.org/10.3171/2009.10.JNS091092
  10. Levi-Montalcini R, Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool 1951;116:321-61. https://doi.org/10.1002/jez.1401160206
  11. Snider WD. Functions of the neurotrophins during nervous system development: what the knockouts are teaching us. Cell 1994;77:627-38. https://doi.org/10.1016/0092-8674(94)90048-5
  12. Nimni ME. Polypeptide growth factors: targeted delivery systems. Biomaterials 1997;18:1201-25. https://doi.org/10.1016/S0142-9612(97)00050-1
  13. Shibayama E, Koizumi H. Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues. Am J Pathol 1996;148:1807-18.
  14. Madduri S, Papaloïzos M, Gander B. Trophically and topographically functionalized silk fibroin nerve conduits for guided peripheral nerve regeneration. Biomaterials 2010;31:2323-34. https://doi.org/10.1016/j.biomaterials.2009.11.073
  15. Jhaveri SJ, Hynd MR, Dowell-Mesfin N, Turner JN, Shain W, Ober CK. Release of nerve growth factor from HEMA hydrogelcoated substrates and its effect on the differentiation of neural cells. Biomacromolecules 2009;10:174-83. https://doi.org/10.1021/bm801101e
  16. Bhang SH, Jeon O, Choi CY, Kwon YH, Kim BS. Controlled release of nerve growth factor from fibrin gel. J Biomed Mater Res A 2007;80:998-1002.
  17. Sakiyama-Elbert SE, Hubbell JA. Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. J Control Release 2000;69:149-58. https://doi.org/10.1016/S0168-3659(00)00296-0
  18. Yang HS, La WG, Bhang SH, Jeon JY, Lee JH, Kim BS. Heparinconjugated fibrin as an injectable system for sustained delivery of bone morphogenetic protein-2. Tissue Eng Part A 2010;16:1225-33. https://doi.org/10.1089/ten.tea.2009.0390
  19. Jeon O, Ryu SH, Chung JH, Kim BS. Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. J Control Release 2005;105:249-59. https://doi.org/10.1016/j.jconrel.2005.03.023
  20. Sakiyama-Elbert SE, Hubbell JA. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release 2000;65:389-402. https://doi.org/10.1016/S0168-3659(99)00221-7
  21. Park MS, Kim SS, Cho SW, Choi CY, Kim BS. Enhancement of the osteogenic efficacy of osteoblast transplantation by the sustained delivery of basic fibroblast growth factor. J Biomed Mater Res B Appl Biomater 2006;79:353-9.
  22. Eckardt H, Ding M, Lind M, Hansen ES, Christensen KS, Hvid I. Recombinant human vascular endothelial growth factor enhances bone healing in an experimental nonunion model. J Bone Joint Surg Br 2005;87:1434-8.

Cited by

  1. Concentrated growth factor increases Schwann cell proliferation and neurotrophic factor secretion and promotes functional nerve recovery in vivo vol.37, pp.2, 2014, https://doi.org/10.3892/ijmm.2015.2438
  2. Controlled Release of BMP-2 from a Heparin-Conjugated Strontium-Substituted Nanohydroxyapatite/Silk Fibroin Scaffold for Bone Regeneration vol.4, pp.9, 2014, https://doi.org/10.1021/acsbiomaterials.8b00459
  3. The Effects of Leukocyte-Platelet Rich Fibrin (L-PRF) on Suppression of the Expressions of the Pro-Inflammatory Cytokines, and Proliferation of Schwann Cell, and Neurotrophic Factors vol.10, pp.None, 2014, https://doi.org/10.1038/s41598-020-59319-2